In the treatment of non-alcoholic steatohepatitis, FGF21 and its analogs have shown encouraging outcomes, and FGF21 can prevent the deterioration of steatosis, inflammation, hepatocyte injury, fibrosis, and cirrhosis in observed non-alcoholic steatohepatitis (Tucker et al., 2019). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.